Regeneron Pharmaceuticals (REGN) said Monday the European Commission granted conditional marketing approval for its experimental therapy, Lynozyfic, to treat adults with relapsed and refractory multiple myeloma.
The company said the approval was based on trial results showing a 71% objective response rate, with 50% of patients achieving a complete response or better.
In the US, the company said the Food and Drug Administration has accepted the marketing application for the therapy and is expected to decide by July 10.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.